Draft Guidance for Industry on Postmarketing Studies and Clinical Trials; Implementation of Section 505(o) of the Federal Food, Drug, and Cosmetic Act; Availability

 
Docket ID: FDA-2009-D-0283
Agency: Food and Drug Administration (FDA)
Parent Agency: Department of Health and Human Services (HHS)
Summary:
Status:OPEN
Docket Details open glossary dialog  
Related RINs: None
Related Dockets: None
Keyword(s): cder200917, postmarketing studies, clinical trials, section 505 (o), implementation, Center for Drug Evaluation and Research
Type: Nonrulemaking
Center: CDER
Docket Item Code: D
 

Primary Documents

View All  (4)

Supporting Documents

 
No documents available.

Comments

View All  (17)

17
Comments Received*
*This count refers to the total comment/submissions received on this docket, as of 11:59 PM yesterday. Note: Agencies review all submissions, however some agencies may choose to redact, or withhold, certain submissions (or portions thereof) such as those containing private or proprietary information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. This can result in discrepancies between this count and those displayed when conducting searches on the Public Submission document type. For specific information about an agency’s public submission policy, refer to its website or the Federal Register document.